These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8292674)

  • 1. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.
    Hagger C; Buckley P; Kenny JT; Friedman L; Ubogy D; Meltzer HY
    Biol Psychiatry; 1993 Nov; 34(10):702-12. PubMed ID: 8292674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.
    Lindenmayer JP; Iskander A; Park M; Apergi FS; Czobor P; Smith R; Allen D
    J Clin Psychiatry; 1998 Oct; 59(10):521-7. PubMed ID: 9818633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of clozapine on cognitive function in schizophrenia.
    Lee MA; Thompson PA; Meltzer HY
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():82-7. PubMed ID: 7961582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia.
    Lee MA; Jayathilake K; Meltzer HY
    Schizophr Res; 1999 May; 37(1):1-11. PubMed ID: 10227103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.
    Hoff AL; Faustman WO; Wieneke M; Espinoza S; Costa M; Wolkowitz O; Csernansky JG
    Neuropsychopharmacology; 1996 Oct; 15(4):361-9. PubMed ID: 8887990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
    Krakowski MI; Czobor P; Nolan KA
    J Clin Psychopharmacol; 2008 Oct; 28(5):485-93. PubMed ID: 18794642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clozapine, cognition, and schizophrenia.
    Launer M
    Br J Psychiatry; 1993 Apr; 162():567-8. PubMed ID: 8481757
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of clozapine in treatment-refractory schizophrenia.
    Kuoppasalmi K; Rimon R; Naukkarinen H; Lang S; Sandqvist A; Leinonen E
    Schizophr Res; 1993 Jun; 10(1):29-32. PubMed ID: 8369229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
    Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
    Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine.
    Delle Chiaie R; Salviati M; Fiorentini S; Biondi M
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):563-8. PubMed ID: 18179309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
    Goff DC; Cather C; Gottlieb JD; Evins AE; Walsh J; Raeke L; Otto MW; Schoenfeld D; Green MF
    Schizophr Res; 2008 Dec; 106(2-3):320-7. PubMed ID: 18799288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.
    Kane JM; Marder SR; Schooler NR; Wirshing WC; Umbricht D; Baker RW; Wirshing DA; Safferman A; Ganguli R; McMeniman M; Borenstein M
    Arch Gen Psychiatry; 2001 Oct; 58(10):965-72. PubMed ID: 11576036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.
    Buchanan RW; Holstein C; Breier A
    Biol Psychiatry; 1994 Dec; 36(11):717-25. PubMed ID: 7858067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.
    Meltzer HY; Bastani B; Kwon KY; Ramirez LF; Burnett S; Sharpe J
    Psychopharmacology (Berl); 1989; 99 Suppl():S68-72. PubMed ID: 2813667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of risperidone on cognition in patients with schizophrenia.
    Stip E; Lussier I
    Can J Psychiatry; 1996 Oct; 41(8 Suppl 2):S35-40. PubMed ID: 8899249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment.
    Kaneda Y; Jayathilak K; Meltzer H
    Psychiatry Res; 2010 Jun; 178(1):57-62. PubMed ID: 20452677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders?
    Anderson VM; McIlwain ME; Kydd RR; Russell BR
    Psychiatry Res; 2015 Dec; 230(3):811-8. PubMed ID: 26564550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of clozapine on symptom clusters in treatment-refractory patients.
    Abraham G; Nair C; Tracy JI; Simpson GM; Josiassen RC
    J Clin Psychopharmacol; 1997 Feb; 17(1):49-53. PubMed ID: 9004057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.